EGFR and myosin II inhibitors cooperate to suppress EGFR-T790M-mutant NSCLC cells.
Chiu HC, Chang TY, Huang CT, Chao YS, Hsu JT.
Mol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.molonc.2012.02.001 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
8 träffarTyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm050936oAn alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B.
Cancer Res · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-05-1346EGFR pharmacogenomics: the story continues to mutate and evolve.
Desai AA, Ratain MJ.
Am J Pharmacogenomics · comparative study; research support, u.s. gov't, p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.2165/00129785-200505020-000076-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A.
J Med Chem · journal article · DOI 10.1021/jm0005555Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.
Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED.
Kidney Int · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1046/j.1523-1755.2000.00829.xIn vitro modulation of cyst formation by a novel tyrosine kinase inhibitor.
Sweeney WE, Futey L, Frost P, Avner ED.
Kidney Int · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1046/j.1523-1755.1999.00577.xIrreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
Discafani CM, Carroll ML, Floyd MB, Hollander IJ, Husain Z, Johnson BD, Kitchen D, May MK, Malo MS, Minnick AA, Nilakantan R, Shen R, Wang YF, Wissner A, Greenberger LM.
Biochem Pharmacol · journal article · DOI 10.1016/s0006-2952(98)00356-6